Revance Therapeutics Inc. (RVNC)
| Bid | 3.65 |
| Market Cap | 381.02M |
| Revenue (ttm) | 243.9M |
| Net Income (ttm) | -287.5M |
| EPS (ttm) | -3.34 |
| PE Ratio (ttm) | -1.092814371257485 |
| Forward PE | -16.59 |
| Analyst | Hold |
| Ask | 3.66 |
| Volume | 0 |
| Avg. Volume (20D) | 2,958,312 |
| Open | 3.65 |
| Previous Close | 3.65 |
| Day's Range | 3.65 - 3.65 |
| 52-Week Range | 2.30 - 7.56 |
| Beta | 0.95 |
About RVNC
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to tre...
Analyst Forecast
According to 9 analyst ratings, the average rating for RVNC stock is "Hold." The 12-month stock price forecast is $6, which is an increase of 64.38% from the latest price.
Stock Forecasts
1 month ago · accessnewswire.com
March 4, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RVNCNEW YORK, NY / ACCESS Newswire / March 3, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal secur...
